Sanofi nears selling 50% controlling stake in Opella to CD&R

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton Dublilier & Rice, known as CD&R. 

The two companies shared that they have signed the share purchase agreement in relation to the $17 billion sale, noting that French public investment bank Bpifrance is expected to participate as a minority shareholder with a 2% stake in Opella, and Sanofi remaining a significant shareholder.

Sanofi said the closing is expected to take place in Q2 2025 at the earliest. Customary regulatory approvals are still required.

[Read more: A Force for Change: Sanofi Consumer Healthcare North America is B Corp Certified]

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries and manages 13 best-in-class manufacturing sites and four research and innovation centers. 

With a portfolio of 100 brands, including Allegra, Doliprane, Novanight, Icy Hot and Dulcolax, Opella is the world's third-largest company in the over-the-counter and vitamins, minerals and supplements market, serving more than half a billion consumers worldwide.

[Read more: Sanofi in discussions to sell a controlling stake in Opella]